Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 13/2010

01-09-2010 | Adis Drug Evaluation

Octreotide Long-Acting Release (LAR)

A Review of its Use in the Management of Acromegaly

Authors: Lily P. H. Yang, Gillian M. Keating

Published in: Drugs | Issue 13/2010

Login to get access

Abstract

Octreotide long-acting release (LAR) [Sandostatin® LAR®] is a somatostatin analogue with a well established clinical profile in patients with acromegaly. It binds to somatostatin receptor subtypes 2 and 5 with high potency to reduce the production and secretion of growth hormone (GH) and insulin-like growth factor (IGF)-I. Octreotide LAR is administered intramuscularly once every 28 days, in contrast to the subcutaneous formulation which requires administration two to three times daily.
In several noncomparative trials, octreotide LAR was effective as primary therapy in normalizing GH and IGF-I levels and reducing tumour volume in patients with acromegaly. In addition, no significant difference was seen between octreotide LAR and surgery or lanreotide long-acting (LA) or lanreotide Autogel® (ATG) in small, randomized or observational, primary therapy trials. In another small, randomized trial, preoperative octreotide LAR followed by surgery was no more effective than surgery alone in terms of normalizing IGF-I levels, except in patients with macroadenoma. Octreotide LAR has also demonstrated good efficacy as postoperative adjuvant therapy, alone or in combination with pegvisomant, in randomized or noncomparative trials. In patients with different treatment histories (mixed populations), the efficacy of octreotide LAR appears to be generally similar to that of lanreotide ATG and greater than that of lanreotide LA, according to data from switching or crossover studies. Also in mixed populations, the efficacy of octreotide LAR was not significantly different to that of pegvisomant in terms of normalizing IGF-I levels in a randomized trial, and octreotide LAR demonstrated good efficacy in combination with cabergoline in a small, sequential-treatment trial. Octreotide LAR was generally well tolerated in clinical trials, with the most commonly occurring adverse events being gastrointestinal or hepatobiliary in nature. Thus, octreotide LAR continues to be a valuable option in the treatment of acromegaly.
Literature
1.
McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003; 63(22): 2473–99PubMedCrossRef
2.
Melmed S. Acromegaly [published erratum appears in N Engl J Med 2007 Feb 22; 356 (8): 879]. N Engl J Med 2006 Dec 14; 355(24): 2558–73PubMedCrossRef
3.
Chanson P, Salenave S, Kamenicky P, et al. Acromegaly. Best Pract Res Clin Endocrinol Metab 2009 Oct; 23(5): 555–74PubMedCrossRef
4.
Feelders RA, Hofland LJ, van Aken MO, et al. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 2009; 69(16): 2207–26PubMedCrossRef
5.
Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004 Feb; 25(1): 102–52PubMedCrossRef
6.
Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008 Jan; 93(1): 61–7PubMedCrossRef
7.
Cook DM. Octreotide long-acting repeatable in acromegaly: achieving optimal control. Endocrinologist 2009 Jun; 19(3): 142–7CrossRef
8.
Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009 May; 94(5): 1509–17PubMedCrossRef
9.
Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-1 on mortality in acromegaly. Eur J Endocrinol 2008 Aug; 159(2): 89–95PubMedCrossRef
10.
Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004 Apr; 89(4): 1613–7PubMedCrossRef
11.
12.
13.
14.
15.
Kaal A, Frystyk J, Skjaerbaek C, et al. Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients. Metabolism 1995 Jan; 44 (1 Suppl. 1): 6–14CrossRef
16.
Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995 Nov; 80(11): 3267–72PubMedCrossRef
17.
Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996 Aug; 45 (8 Suppl. 1): 67–71PubMedCrossRef
18.
19.
20.
21.
Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009 Dec; 25(12): 2989–99PubMedCrossRef
22.
Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003 Feb; 24(1): 28–47PubMedCrossRef
23.
Gola M, Bonadonna S, Mazzioti G, et al. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006 Jan; 29(1): 86–93PubMed
24.
Maison P, Tropeano A-I, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007 May; 92(5): 1724–8CrossRef
25.
Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007 May; 92(5): 1592–9PubMedCrossRef
26.
Danila DC, Haidar JN, Zhang X, et al. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 2001 Jul; 86(7): 2976–81PubMedCrossRef
27.
Fløgstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995 Dec; 80(12): 3601–7PubMedCrossRef
28.
Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR®: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995 Jan; 44 (1 Suppl. 1): 18–26CrossRef
29.
Grass P, Marbach P, Bruns C, et al. Sandostatin® LAR® (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996; 45 (8 Suppl. 1): 27–30PubMedCrossRef
30.
Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010 Jul; 95(7): 3141–8PubMedCrossRef
31.
Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002 Oct; 87(10): 4554–63PubMedCrossRef
32.
Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006 Mar; 64(3): 342–51CrossRef
33.
Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007 Nov; 157(5): 579–87PubMedCrossRef
34.
Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006 Apr; 91(4): 1397–403PubMedCrossRef
35.
Gilbert J, Ketchen M, Kane P, et al. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary 2003; 6(1): 11–8PubMedCrossRef
36.
Grottoli S, Celleno R, Gasco V, et al. Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. J Endocrinol Invest 2005 Dec; 28(11): 978–83PubMed
37.
Jenkins PJ, Emery M, Howling SJ, et al. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res 2004; 62(5): 227–32PubMedCrossRef
38.
Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007 Jun; 66(6): 859–68CrossRef
39.
Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 2009 May; 70(5): 757–68CrossRef
40.
Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002 Jan; 56(1): 65–71CrossRef
41.
Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-1 levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 2009 Oct; 94(10): 3746–56PubMedCrossRef
42.
Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008 Aug; 93(8): 2984–90PubMedCrossRef
43.
Yin J, Su CB, Xu ZQ, et al. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery. Chin Med Sci J 2005 Mar; 20(1): 23–6PubMed
44.
Jallad RS, Musolino NR, Kodaira S, et al. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 2007 Aug; 67(2): 310–5CrossRef
45.
Yetkin DO, Boysan SN, Tiryakioglu O, et al. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. Endocr J 2007 Jun; 54(3): 459–64PubMedCrossRef
46.
Trainer PJ, Ezzat S, D’Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 2009 Oct; 71(4): 549–57CrossRef
47.
Ronchi CL, Orsi E, Giavoli C, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 2003 Jun; 26(6): 533–8PubMed
48.
Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008 Mar; 68(3): 473–80CrossRef
49.
Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004 Sep; 151(3): 317–24PubMedCrossRef
50.
Ashwell SC, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004 Apr; 150(4): 473–80PubMedCrossRef
51.
Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120mg in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007 Oct; 67(4): 512–9
52.
van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004 Apr; 150(4): 489–95PubMedCrossRef
53.
Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000 Nov; 53(5): 577–86CrossRef
54.
Cozzi R, Dallabonzana D, Attanasio R, et al. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999 Sep; 141(3): 267–71PubMedCrossRef
55.
Kendall-Taylor P, Miller M, Gebbie J, et al. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000 Oct; 3(2): 61–5PubMedCrossRef
56.
Ronchi C, Epaminonda P, Cappiello V, et al. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002 Jun; 25(6): 502–7PubMed
57.
Turner HE, Vadivale A, Keenan J, et al. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 1999 Sep; 51(3): 275–80CrossRef
58.
Ghigo E, Biller BMK, Colao A, et al. Comparison of peg-visomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest 2009 Dec; 32(11): 942–33
59.
Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuro-endocrinology 2009; 90(1): 82–92
60.
Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000 Sep; 85(9): 3132–40PubMedCrossRef
61.
Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001 Jun; 86(6): 2779–86PubMedCrossRef
62.
Davies PH, Stewart SE, Lancranjan I, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR®) for the management of acromegaly. Clin Endocrinol (Oxf) 1998 Mar; 48(3): 311–6CrossRef
63.
Fløgstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997 Jan; 82(1): 23–8PubMedCrossRef
64.
Lancranjan I, Atkinson AB. Results of a European multi-centre study with Sandostatin LAR in acromegalic patients: Sandostatin LAR Group. Pituitary 1999; 1(2): 105–14PubMedCrossRef
65.
Mangupli R, Lisette A, Ivett C, et al. Improvement of acromegaly after octreotide LAR treatment. Pituitary 2003; 6(1): 29–34PubMedCrossRef
66.
Jallad RS, Musolino NRC, Salgado LR, et al. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 2005 Aug; 63(2): 168–75CrossRef
67.
Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005 Aug; 90(8): 4465–73PubMedCrossRef
68.
Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009 May; 94(5): 1500–8PubMedCrossRef
69.
Valentim J, Passos V, Mataveli F, et al. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 2008 Dec; 52(9): 1452–60PubMedCrossRef
Metadata
Title
Octreotide Long-Acting Release (LAR)
A Review of its Use in the Management of Acromegaly
Authors
Lily P. H. Yang
Gillian M. Keating
Publication date
01-09-2010
Publisher
Springer International Publishing
Published in
Drugs / Issue 13/2010
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11204510-000000000-00000

Other articles of this Issue 13/2010

Drugs 13/2010 Go to the issue

Therapy In Practice

Pyelonephritis in Pregnancy

Adis Drug Evaluation

Bendamustine

Review Article

Opioid Formulations Designed to Resist/Deter Abuse

Adis Drug Evaluation

Tapentadol Immediate Release

Leading Article

Novel Antiretroviral Combinations in Treatment-Experienced Patients with HIV Infection

ADis Drug Profile

Guanfacine Extended-Release